Miller M S, Gressani K M, Leone-Kabler S, Townsend A J, Malkinson A M, O'Sullivan M G
Departments of Cancer Biology and Physiology and Pharmacology Comprehensive Cancer Center, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1082, USA.
Exp Lung Res. 2000 Dec;26(8):709-30. doi: 10.1080/01902140150216774.
Research conducted by this laboratory over the past decade has demonstrated the high susceptibility of the fetus to lung tumor formation following in utero exposure of the resistant C57BL/6 and DBA/2N strains of mice to 3-methylcholanthrene (MC). In this review, we describe our more recent studies on the effects of MC and cotreatment with the lung tumor promoter, butylated hydroxytoluene (BHT), on lung tumor formation in the intermediately susceptible BALB/c strain of mice, and the determination of the potential carcinogenicity of the heterocyclic amine, 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in resistant mouse strains. BALB/c mice showed a similar incidence of lung tumors, both in terms of percentage of mice with tumors and number of tumors per mouse, as found in the resistant [D2 x B6D2F1]F2 mice. Ki-ras point mutations were found in 56% (20/36) of BALB/c lung lesions compared with an incidence of 79% in [D2 x B6D2F1]F2 mice. BALB/c lung lesions demonstrated a similar association of Ki-ras mutations with tumor stage. Interestingly, a strain-dependent difference was observed in the mutational spectrum, where 62% and 38% of the lesions in BALB/c mice exhibited G-->C and G-->T transversions, respectively, in contrast with the 16% and 84% incidences observed in [D2 x B6D2F1]F2 mice. BHT had no statistically significant effect on tumor incidence, multiplicity, or Ki-ras mutational spectrum in BALB/c mice treated in utero with MC, although a trend toward increased tumor multiplicity was observed. Finally, experiments initiated to assess the transplacental carcinogenicity of IQ in D2B6F1 mice demonstrated that 1 year after birth, no macroscopically or microscopically visible liver, lung, or colon tumors were found in the transplacentally treated offspring, nor was induction of Cyp1a1, Cyp1b1, or glutathione S-transferases (GSTs) in fetal lung and liver tissues observed. This implies that at least under these experimental conditions, IQ may not be an important transplacental carcinogen. Overall, these data demonstrate that mutagenic damage to Ki-ras is a critical early event mediating murine lung tumorigenesis in both sensitive and resistant strains. Strain-dependent differences in the Ki-ras mutational spectrum may be associated with their differential susceptibility to lung tumor initiation.
本实验室在过去十年中进行的研究表明,抗性C57BL/6和DBA/2N品系的小鼠在子宫内暴露于3-甲基胆蒽(MC)后,其胎儿对肺部肿瘤形成高度敏感。在这篇综述中,我们描述了我们最近关于MC以及与肺部肿瘤促进剂丁基羟基甲苯(BHT)联合处理对中度敏感的BALB/c品系小鼠肺部肿瘤形成的影响,以及对抗性小鼠品系中杂环胺2-氨基-3-甲基咪唑[4,5-f]喹啉(IQ)潜在致癌性的测定。BALB/c小鼠肺部肿瘤的发生率,无论是有肿瘤的小鼠百分比还是每只小鼠的肿瘤数量,都与抗性[D2 x B6D2F1]F2小鼠相似。在BALB/c肺部病变中,56%(20/36)发现了Ki-ras点突变,而在[D2 x B6D2F1]F2小鼠中的发生率为79%。BALB/c肺部病变显示Ki-ras突变与肿瘤分期有类似的关联。有趣的是,在突变谱中观察到了品系依赖性差异,其中BALB/c小鼠中62%和38%的病变分别表现为G→C和G→T颠换,相比之下,在[D2 x B6D2F1]F2小鼠中观察到的发生率分别为16%和84%。对于在子宫内用MC处理的BALB/c小鼠,BHT对肿瘤发生率、肿瘤数量或Ki-ras突变谱没有统计学上的显著影响,尽管观察到肿瘤数量有增加的趋势。最后,为评估IQ在D2B6F1小鼠中的经胎盘致癌性而开展的实验表明,出生1年后,在经胎盘处理的后代中未发现肉眼或显微镜下可见的肝脏、肺部或结肠肿瘤,在胎儿肺和肝组织中也未观察到Cyp1a1、Cyp1b1或谷胱甘肽S-转移酶(GST)的诱导。这意味着至少在这些实验条件下,IQ可能不是一种重要的经胎盘致癌物。总体而言,这些数据表明,对Ki-ras的诱变损伤是介导敏感和抗性品系小鼠肺部肿瘤发生的关键早期事件。Ki-ras突变谱中的品系依赖性差异可能与其对肺部肿瘤起始的不同易感性有关。